SecBot SecBot
8-K ·Filed Apr 27, 2026

XOMAP

XOMA Royalty Corp
BULLISH
Impact 8/10
Horizonmonths Processed6mo ago SEC0001193125-26-179085
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

Monitor for shareholder approval and regulatory clearances, as the deal is expected to close in Q3 2026. The significant premium and immediate accretion signal strong confidence in the combined company's growth, making this a key event for Ligand's stock. Watch for updates on the Janssen litigation, as its outcome will determine the value of the CVRs distributed to XOMA shareholders.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$25.25
T+0 close · Apr 27, 2026 · via day close
Latest settled
−1.07%
T+60 · $24.98
Vs SPY
−5.85%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $25.25entry
  2. T+1 · 7mo ago −0.01%α +0.48% · $25.25
  3. T+5 · 7mo ago −0.04%α −0.44% · $25.24
  4. T+20 · 6mo ago +0.44%α −4.52% · $25.36
  5. T+60 · 4mo ago −1.07%α −5.85% · $24.98

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ligand Pharmaceuticals is acquiring XOMA Royalty in an all-cash transaction valued at approximately $739 million, with XOMA shareholders receiving $39.00 per share plus a contingent value right (CVR) tied to potential litigation proceeds. The deal, unanimously approved by both boards and supported by major shareholders, is expected to close in Q3 2026 and is immediately accretive to Ligand's earnings.

Key Financial Metrics

Deal Value
$739.0M
Premium
14%
Deal Type
acquisition

Key Facts

  • Ligand Pharmaceuticals (LGND) is acquiring XOMA Royalty (XOMAP) for $39.00 per share in cash, representing a 14% premium to the 30-day volume-weighted average price.
  • The total equity value of the transaction is approximately $739 million.
  • XOMA shareholders will also receive one non-transferable Contingent Value Right (CVR) per share, entitling them to 75% of net proceeds from ongoing litigation against Janssen Biotech.
  • The deal is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals.
  • Ligand expects the acquisition to be immediately accretive to its 2026 adjusted EPS and accretive by $1.50 per share in 2027.

Financial Impact

Approximately $739 million total equity value. $39.00 per share in cash for XOMA shareholders, plus a CVR for potential future litigation proceeds.

equity_valueper_share_priceaccretion_to_eps

Risk Factors

  • The deal is subject to customary closing conditions, including shareholder approval and regulatory clearances, which could delay or prevent completion.
  • The value of the CVRs is contingent on the outcome of the Janssen Biotech litigation, which is uncertain and could result in no additional proceeds for XOMA shareholders.
  • Integration risks exist, as combining the two royalty portfolios may not yield the anticipated synergies.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-179085
Document: d139894d8k.htm0001193125-26-179085
Document: d139894dex101.htm0001193125-26-179085
Document: d139894dex991.htm0001193125-26-179085
Document: 0001193125-26-179085-index-headers.html0001193125-26-179085
Document: 0001193125-26-179085-index.html0001193125-26-179085
Document: 0001193125-26-179085.txt0001193125-26-179085

Track record

6 reports on XOMAP

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +0.47% at T+20 after the May 26, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Jun 10, 202622w ago DEFM14A Bullish 8/10 Entry $25.51 to $24.98 ▼ −2.07% −3.96% vs SPY
  2. May 26, 202624w ago 425 Bullish 7/10 Entry $25.36 to $25.48 ▲ +0.47% +2.42% vs SPY
  3. May 18, 202626w ago DEFA14A Neutral 4/10 Entry $25.38 to $25.40 ▲ +0.08% −1.50% vs SPY
  4. Apr 27, 202629w ago DEFA14A Bullish 8/10 Entry $25.25 to $25.36 ▲ +0.44% −4.52% vs SPY
  5. Apr 27, 202629w ago 8-K Bullish 8/10 Viewing Entry $25.25 to $25.36 ▲ +0.44% −4.52% vs SPY
  6. Mar 30, 202633w ago DEFA14A Neutral 3/10 Entry $25.74 to $25.62 ▼ −0.47% −9.89% vs SPY
Showing 6 of 6

US Market Status

Market Closed · Opens in 7h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026